Sysmex adds FDA-cleared CellaVision DC-1 to portfolio

Nov. 20, 2020—<u>Sysmex America</u> has added the FDA 510(k)-cleared CellaVision DC-1 to its portfolio of CellaVision products for low-volume hematology labs.

The CellaVision DC-1 eliminates the majority of manual steps done traditionally by lab technicians who perform blood cell differentials and standardizes differential results by automating cell location and preclassification.

"The solution for both standalone and networked installation, the CellaVision DC-1 closes the technology gap between larger and smaller labs," Andy Hay, chief operating officer of Sysmex America, said in a press statement. "The CellaVision DC-1 provides labs high-quality digital imaging for improved efficiency, quality, connectivity, and staff proficiency."

The analyzer is available now in the United States and Canada.